Physician profile

David A Worth

Rheumatology · Union, NJ

NPI 1861406902

$6,371.32

in general payments reported to CMS, 2019-2025

29 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $1,041.32 2019-2021
Abbvie INC. $953.54 2019-2021
Pfizer INC. $511.53 2019-2021
Janssen Biotech, INC. $500.95 2019-2021
Glaxosmithkline, LLC. $485.93 2019-2021
Novartis Pharmaceuticals Corporation $480.41 2019-2022
E.R. Squibb & Sons, L.L.C. $451.32 2019-2021
Lilly USA, LLC $371.89 2019-2021
Genzyme Corporation $307.13 2019-2021
Horizon Therapeutics Plc $292.36 2019-2021
Ucb, INC. $185.01 2020-2021
Genentech USA, INC. $143.38 2019-2020
Sobi, INC $69.91 2019-2021
Mallinckrodt Hospital Products INC. $68.91 2021
Hikma Pharmaceuticals USA $56.33 2019-2020
Show all 29 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David A Worth

$6,371.32

in general payments reported 2019-2025

Years
2019-2022
Top company
Amgen INC.

https://glasscript.com/doctor/129999/david-a-worth

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.